Diabetes · Phase 3
REIMAGINE 3: combination added to basal insulin
NCT06323161 ↗ · Combined treatment
What was tested?
Cagrilintide plus semaglutide versus placebo added to basal insulin, with or without metformin. ↗
Registered primary question: Change in HbA1c at week 40. ↗
What the reviewed report found
Journal year 2026 · Article summary reviewed 2026-09-15
Under the efficacy analysis, HbA1c fell by 2.33 and 2.10 percentage points in the combination groups versus 0.66 with placebo. Gastrointestinal events were common; no severe hypoglycemia was reported.↗
Keep in context: This report uses an efficacy estimand and a population already receiving basal insulin. Its estimates answer a different question from the REDEFINE weight-management trials. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 274 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2026-09-09; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
REIMAGINE 3: combination treatment alongside basal insulin
- Design in the report
- A blinded randomized placebo-controlled phase 3a trial assessed 40-week HbA1c change under NCT06323161.↗
- Participants in the report
- The study randomized 274 adults with type 2 diabetes receiving basal insulin, with or without metformin.↗
- Limitations
- The report recorded one death due to malignancy in an active group, considered unrelated to treatment. Absence of severe hypoglycemia in this study does not establish absence of risk, and the findings are not an individualized treatment recommendation.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin ↗
Protocol identifier: NN9388-7637. Sponsor: Novo Nordisk A/S.
Retrieved 2026-09-20; SHA-256 f970ccc780794dde18e26544bb99fb94a7aae7e57a0a0abf185b3cd3ac9e9cb3.
PMID 42251856
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 42251856. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 9f2cda3784ed8d76bc0e31467119bff480bfd5319cfb18fe87f2146faa74a7ad.